Official Title
Corticosteroids During Covid-19 Viral Pneumonia Related to SARS-Cov-2 Infection
Brief Summary

Infection with the SARS-Cov-2 virus, responsible of severe acute respiratory distress syndrome (SARS), is an emerging infectious disease called Covid-19 and declared as pandemic by the World Health Organization on March 11, 2020. This pandemic is responsible of significant mortality. In France, several thousand patients are hospitalized in intensive care units, and their number continues to increase. Mortality during Covid-19 is mainly linked to acute respiratory distress syndrome, which frequency is estimated in France to occur in 6% of infected patients. Comorbidities such as cardiovascular conditions, obesity and diabetes increase susceptibility to severe forms of Covid-19 and associated mortality. Therapeutic management has three components: symptomatic management, including supplementary oxygen therapy and in case of respiratory distress mechanical ventilation; the antiviral approach; and immunomodulation, aiming at reducing inflammation associated with viral infection, which is considered to take part in severe presentations of the disease. During Covid-19 viral pneumonia related to SARS-COv-2, there is a significant release of pro-inflammatory cytokines in the acute phase of viral infection, which could participate in viral pneumonia lesions. In children with less mature immune system than adults, SARS-Cov-2 infection is less severe. The current prevailing assumption is that severe forms of Covid-19 may not only be related to high viral replication, but also to an excessive inflammatory response favoring acute lung injury and stimulating infection. The investigators hypothesize that early control of the excessive inflammatory response may help reducing the risk of acute respiratory distress syndrome. The investigators will evaluate the benefit, safety and tolerability of corticosteroid therapy to reduce the rate of subjects hospitalized for Covid-19 viral pneumonia who experience clinical worsening with a need of high-flow supplemental oxygen supplementation or transfer in intensive care units for respiratory support.

Viral Pneumonia Human Coronavirus

Drug: Prednisone

The experimental group will receive oral prednisone during 10 days (0.75 mg/kg/day during 5 days then 20 mg/day during 5 more days)

Other: Control group

The control group will receive standard of care according to the international recommendations and practices of the investigational site. No corticosteroid therapy can be prescribed in this group.

Eligibility Criteria

Inclusion Criteria:

- Age ≥ 18 years old,

- Hospitalization for COVID-19 infection confirmed by RT-PCR or other virological

- Peripheral saturation by pulse oximeter SpO2 ≤ 94% in ambient air measured twice at
5-15 min intervals, or PaO2 / FiO2 <300 mmHg,

- Abnormalities on the chest x-ray or CT scan suggestive of viral pneumonia,

- Signed informed consent by the patient.

Exclusion Criteria:

- Covid-19 infection with first symptoms lasting for more than 9 days according to the
patient's interview; D1 of symptoms is defined by the first day with fever, cough,
shortness of breath, and / or chills related to Covid-19 infection;

- Patients with primary or secondary immune deficiency, including: HIV, chronic
hematological disease, solid organ transplant, ongoing immunosuppressive therapy,

- Long-term corticosteroid therapy defined by a prescription of more than 10 mg/d
(prednisone equivalent),

- Suspected or confirmed infection with bacteria, fungal agents or viruses (in addition
to Covid-19),

- Known contraindication to systemic corticosteroids,

- Systolic blood pressure <80 mmHg,

- SpO2 <90% under 5 L / min of oxygen using medium concentration mask, or higher oxygen

- Patient on long-term oxygen therapy,

- Ongoing mechanical ventilation,

- Ongoing septic shock ongoing,

- Ongoing multi-organ failure ongoing,

- Participating in other COVID-19 therapeutic clinical trial

- Pregnant or breast-feeding woman (oral diagnosis),

- No affiliation or beneficiary of health insurance,

Eligibility Gender
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A

Hôpital Pneumologique et Cardiovasculaire Louis Pradel
Bron, France

Groupement Hospitalier Nord
Lyon, France

Hôpital Edouard Herriot
Lyon, France

Hôpital St Joseph Saint Luc
Lyon, France

Hôpital St Joseph
Marseille, France

Centre hospitalier Lyon Sud
Pierre-Bénite, France

CHU St Etienne
Saint-Étienne, France

Clinique Charcot
Sainte-Foy-lès-Lyon, France

CHG Vienne
Vienne, France

Villeurbanne, France

Clinique des Portes du Sud
Vénissieux, France

CH Annecy-Genevois
Épagny, France

Jean-François MORNEX, Principal Investigator
Hospices Civils de Lyon

Hospices Civils de Lyon
NCT Number
viral pneumology
MeSH Terms
Pneumonia, Viral